Close Menu

NEW YORK – Clinical-stage precision oncology company Revolution Medicines said on Monday that its investigational SHP2 inhibitor RMC-4630 will be used in the Phase I/IB SHERPA trial conducted by the Netherlands Cancer Institute.

The trial, which is expected to start in the second half of 2020, will investigate RMC-4630 in combination with an investigational ERK inhibitor in patients with solid tumors harboring RAS mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.